Insys Therapeutics (INSY) Downgraded to “Buy” at ValuEngine

ValuEngine lowered shares of Insys Therapeutics (NASDAQ:INSY) from a strong-buy rating to a buy rating in a report released on Wednesday.

INSY has been the subject of a number of other reports. Zacks Investment Research upgraded Insys Therapeutics from a sell rating to a hold rating in a research note on Thursday, October 11th. Jefferies Financial Group reiterated a buy rating and issued a $10.00 price target on shares of Insys Therapeutics in a research note on Friday, August 10th. Piper Jaffray Companies set a $4.00 price target on Insys Therapeutics and gave the company a sell rating in a research note on Saturday, August 11th. Finally, Royal Bank of Canada reiterated a buy rating and issued a $9.00 price target on shares of Insys Therapeutics in a research note on Thursday, August 9th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company. The stock has an average rating of Hold and a consensus price target of $7.67.

Insys Therapeutics stock opened at $6.71 on Wednesday. Insys Therapeutics has a one year low of $5.04 and a one year high of $14.00. The stock has a market capitalization of $487.95 million, a price-to-earnings ratio of -13.69 and a beta of 1.67.

Insys Therapeutics (NASDAQ:INSY) last released its quarterly earnings results on Monday, November 5th. The specialty pharmaceutical company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). Insys Therapeutics had a negative net margin of 128.88% and a negative return on equity of 266.60%. The business had revenue of $18.30 million during the quarter, compared to analysts’ expectations of $24.05 million. During the same quarter last year, the business posted ($2.30) earnings per share. The company’s quarterly revenue was down 40.4% compared to the same quarter last year. As a group, equities research analysts predict that Insys Therapeutics will post -1.32 EPS for the current year.

Several large investors have recently made changes to their positions in the company. Bridgeway Capital Management Inc. raised its stake in shares of Insys Therapeutics by 11.2% in the third quarter. Bridgeway Capital Management Inc. now owns 84,700 shares of the specialty pharmaceutical company’s stock worth $854,000 after purchasing an additional 8,500 shares during the last quarter. BNP Paribas Arbitrage SA raised its stake in shares of Insys Therapeutics by 47.4% in the second quarter. BNP Paribas Arbitrage SA now owns 31,105 shares of the specialty pharmaceutical company’s stock worth $225,000 after purchasing an additional 10,001 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Insys Therapeutics in the third quarter worth about $113,000. Creative Planning purchased a new position in shares of Insys Therapeutics in the third quarter worth about $153,000. Finally, Tower Research Capital LLC TRC purchased a new position in shares of Insys Therapeutics in the second quarter worth about $131,000. Hedge funds and other institutional investors own 18.45% of the company’s stock.

About Insys Therapeutics

Insys Therapeutics, Inc, a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS.

Further Reading: Systematic Risk and Investors

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Insys Therapeutics (NASDAQ:INSY)

Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply